Evidence map›Paper›PMID 35273603›Full record

ArticleFrontiers in immunology2022

A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination.

Melissa M Lemke, Robert M Theisen, Emily R Bozich, Milla R McLean, Christina Y Lee, Ester Lopez, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Sven Kratochvil and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Melissa M LemkeDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Robert M TheisenDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Emily R BozichDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Milla R McLeanDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Christina Y LeeDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Ester LopezDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Supachai Rerks-NgarmDepartment of Disease Control, Ministry of Public Health, Bangkok, Thailand.
Punnee PitisuttithumVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Sven KratochvilThe Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, United States.
Bruce D WinesImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
P Mark HogarthImmune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.
Stephen J KentDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Amy W ChungDepartment of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · USPeter Doherty Institute · AUUniversity of Melbourne · AUArmed Forces Research Institute of Medical Science · THMahidol University · THMinistry of Public Health · THMonash University · AURagon Institute of MGH, MIT and Harvard · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fc-mediated immune functions have been correlated with protection in the RV144 HIV vaccine trial and are important for immunity to a range of pathogens. IgG antibodies (Abs) that form complexes with Fc receptors (FcRs) on innate immune cells can activate Fc-mediated immune functions. Genetic variation in both IgGs and FcRs have the capacity to alter IgG-FcR complex formation

Indexed as

AIDS VaccinesReceptors, IgGHumansImmunoglobulin GReceptors, FcVaccinationAIDS VaccinesImmunoglobulin GReceptors, FcReceptors, IgGADCCFc receptorFc receptor polymorphismHIVIgG1 allotypeRV144systems serologyvaccine boosting

Identifiers

PMID35273603
PMCPMC8902241
OpenAlexW4213384718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.